Biolam, the French group of medical laboratories, accelerates
In Hauts-de-France and Normandy, Daniel Attias and Gimv (a Belgian European investment company with experience in private equity and venture capital) continue their organic and external growth strategy, allowing Biolam - a group of medical laboratories - to exceed EUR 60 million in revenue (pro forma of the latest acquisitions).
In 2019, Daniel Attias was supported by Gimv in his first MBI takeover of the Biolam group of laboratories in Amiens, which he started from the ground up in 2019. Didier Thibaud joined Biolam in Normandy in 2020 to strengthen the company's presence.
This team is currently pursuing an aggressive growth strategy. Biolam completed three new acquisitions in 2021, following four acquisitions and four laboratory creations in 2020.
With the acquisition of Boyer Laboratories, the group has strengthened its position in Normandy, adding approximately EUR 8 million in revenue. Biolam acquired the Mine laboratories in the Hauts-de-France region, where it began its expansion by opening two laboratories (Marly and La Madeleine), as well as acquiring the Tabardel and Viart laboratories in Béthune.
Ambitious management teams
In 2022, Biolam plans to expand organically by opening six new laboratories, negotiating several acquisitions, and making significant investments in the renewal of its industrial equipment in Normandy and the Hauts-de-France. The success of this buy-and-build platform demonstrates that Gimv Health & Care, in collaboration with ambitious management teams, is an expert in European consolidation projects.
Gautier Lefebvre, Partner at Gimv, and Kevin Klein, Principal at Gimv, state: "We are impressed by the trajectory of Biolam, which, under the leadership of Daniel Attias and Didier Thibaud, continues to grow extremely fast while investing heavily in its teams and tools in order to build a high quality healthcare offering.
This entrepreneurial adventure is a perfect illustration of our ability to support managers in rapid external growth strategies. Over the past two years, Gimv's Health & Care team has completed 32 acquisitions via 6 build-up platforms.”
Daniel Attias, Chairman of the Biolam Group, says: "We have already exceeded the targets we initially set ourselves with the Gimv team, which is a sign of a very effective collaboration. We start 2022 with great ambitions in a sanitary context where our willingness to invest, our agility and the total engagement of our teams are more necessary than ever.”
Note: Content may be edited for style and length.
Source
